Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial (Q35066875)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

based on heuristic

inferred from title

author name string

Vakaramoko Diaby

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Georges Adunlin

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Alberto J Montero

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

101-108

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0123-9

21 January 2018

Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0123-9

21 January 2018

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0123-9

21 January 2018

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0123-9

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0123-9

21 January 2018

A new look at the statistical model identification

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0123-9

21 January 2018

Estimating the Dimension of a Model

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0123-9

21 January 2018

Survival models in health economic evaluations: balancing fit and parsimony to improve prediction

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0123-9

21 January 2018

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24338265

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40273-013-0123-9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35066875&oldid=2197211135"